⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
GLPG
GILD
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX
Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50, Recognizing the Most Influential Advertisers Reaching Asian American Consumers
accessnewswire.com
GILD
PG
Breast Cancer Canada’s annual Walk-a-Thon to Mother’s Day returns to advance breast cancer research.
businesswire.com
AMGN
MRK
PFE
BMY
GILD
ABBV
AZN
JNJ
LULU
Form 8-K
sec.gov
GILD
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis
accessnewswire.com
BMY
MRK
PFE
JNJ
ABBV
AMGN
GILD
REGN
BIIB
LLY
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
businesswire.com
GILD
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
KYMR
GILD
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
businesswire.com
GILD